^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gevokizumab (VPM087)

    i
    Other names: VPM087, XOMA 052, XMA005.2, XOMA 052 Mab, XOMA-052, S-78989, XMA 005.2, XMA 052, S 78989, VPM 087, S78989, VPM-087, XMA-005.2, XOMA052, XMA-052, XMA052
    Associations
    News

    Trials

    Company:
    Novartis, Xoma
    Drug class:
    IL-1β inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (NCT03798626)
    Phase 1
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    05/22/2019
    Primary completion :
    03/01/2023
    Completion :
    12/30/2024
    CRP
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)